Feb 19 (Reuters) - Recce Pharmaceuticals Ltd RCE.AX:
RECCE PHARMACEUTICALS REPORTS POSITIVE DATA FROM PHASE II TRIAL OF RECCE® 327 GEL IN ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS, SUPPORTING ACCELERATED COMMERCIALIZATION PATHWAY
RECCE PHARMACEUTICALS LTD - R327G ACHIEVES 93% PRIMARY EFFICACY ENDPOINT IN 14 DAYS
RECCE PHARMACEUTICALS LTD - R327G SAFE AND WELL TOLERATED WITH NO SERIOUS ADVERSE EVENTS
Source text: ID:nGNX6kyg2r
Further company coverage: RCE.AX
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.